| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 16 | GlobeNewswire (Europe) | SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| Mo | Travere Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Travere Therapeutics, Inc.: Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress | 1 | GlobeNewswire (USA) | ||
| 08.05. | Travere Therapeutics, Inc.: Travere Therapeutics to Present at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 07.05. | Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts | 1 | Benzinga.com | ||
| 07.05. | Earnings call: Travere Therapeutics sees robust growth in Q1 2024 | 1 | Investing.com | ||
| 06.05. | Travere Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 06.05. | Travere Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Travere Therapeutics Non-GAAP EPS of $1.51 beats by $2.30, revenue of $41.37M misses by $2.25M | 2 | Seeking Alpha | ||
| 06.05. | Travere Therapeutics, Inc.: Travere Therapeutics Reports First Quarter 2024 Financial Results | 23 | GlobeNewswire (Europe) | FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024... ► Artikel lesen | |
| 06.05. | Travere Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.05. | Travere Therapeutics Q1 2024 Earnings Preview | 2 | Seeking Alpha | ||
| 29.04. | Travere Therapeutics, Inc.: Travere Therapeutics to Report First Quarter 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 24.04. | Travere Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.04. | Travere Therapeutics, Inc.: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | 4 | GlobeNewswire (USA) | ||
| 24.04. | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy | 98 | PR Newswire | First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful... ► Artikel lesen | |
| 17.04. | Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know | 1 | Benzinga.com | ||
| 04.04. | Travere Therapeutics, Inc.: Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International | 1 | GlobeNewswire (USA) | ||
| 03.04. | Travere Therapeutics, Inc.: Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association | 2 | GlobeNewswire (USA) | ||
| 13.03. | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 69 | GlobeNewswire (Europe) | SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 6.060 |
| EVOTEC | 4.995 |
| TUI | 4.679 |
| PLUG POWER | 3.291 |
| AMC ENTERTAINMENT | 2.978 |
| NEL | 2.895 |
| BAYER | 2.275 |
| SIEMENS ENERGY | 2.145 |
| RHEINMETALL | 2.010 |
| COMMERZBANK | 1.816 |
| NVIDIA | 1.778 |
| AIXTRON SE | 1.584 |
| ALLIANZ | 1.540 |
| DEUTSCHE BANK | 1.490 |
| RWE | 1.479 |
| MERCEDES-BENZ | 1.421 |
| THYSSENKRUPP | 1.404 |
| THYSSENKRUPP NUCERA | 1.310 |
| BYD | 1.280 |
| SUPER MICRO COMPUTER | 1.213 |
| VOLKSWAGEN | 1.148 |
| RENK GROUP | 1.123 |
| NORDEX | 1.050 |
| DEUTSCHE TELEKOM | 957 |
| SFC ENERGY | 921 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
